Estimated Investment Need to Increase England's Capacity to Diagnose Eligibility for an Alzheimer's Treatment to G7 Average Capacity Levels.

ABSTRACT:

Background

As disease-modifying Alzheimer's (AD) treatments are becoming available, concerns have been raised that even high-income countries lack the diagnostic capacity to accurately identify eligible patients in a timely manner.

Objectives

We analyze how much NHS England would have to invest in capacity for AD specialists, biomarker testing with PET scans or CSF testing and MRI scans to reach G7 average levels and estimate the effect on wait times in the diagnostic process.

Design

Desk research and expert interviews for cost and capacity data. Markov model to estimate wait times.

Setting

NHS England.

Measurements

AD specialists, and PET and MRI scanners per capita in G7 countries and wait times in England under different investment scenarios.

Resul

SUBMITTER: Mattke S 

PROVIDER: S-EPMC11266384 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature